← All trials
NCT02933333
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2016
- Primary completion
- Aug 1, 2018
- Completion date
- Aug 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 405
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Jiao Tong UniversityLead sponsor
- Qingdao UniversityOverall official - principal investigator
- Shandong Provincial HospitalOverall official - principal investigator
- Shandong Province Qianfoshan HospitalOverall official - principal investigator
- Soochow UniversityOverall official - principal investigator
- Xiamen UniversityOverall official - principal investigator
- Zhengzhou UniversityOverall official - principal investigator
- Jiangxi Children's HospitalOverall official - principal investigator
- Nanjing Medical UniversityOverall official - principal investigator
- Fudan UniversityOverall official - principal investigator
- Jiao Tong UniversityReponsible party - principal investigator
- Jiao Tong UniversityStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.